|
Excuse me, harkenman??? This WSJ article is nothing more than a replay of
last week's news. It's not going to sink anything. And as for you having said
things included in this article, I've gone back and read a handful of your
posts. To be honest, I'm very hard pressed to find a single rational
statement that you've made about the prospects for Myotrophin. Let's look at some
facts: (1) CEPH and the FDA still have to negotiate over the terms to
bring Myo to the U.S. market,
(2) CEPH is currently filing for
European approval (which, IMO, is highly likely), (3) Myo is currently in
a Phase III trial in Japan which may provide support for U.S. approval, (4) CEPH and RPR are in negotiations for a combo trial, (5) the FDA has recently
certified a CHIR manufacturing plant giving them increased Myo production capacity. The story's not over by a long shot. In the future, harkenman, how about sticking with rational, factual comments??? Rudy |
